Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07488481

Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission

Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University Health Network, Toronto General Hospital, Ajmera Transplant Centre

Toronto, Ontario, M5G 2N2, Canada

Location contact

Ilona Bahinskaya, MSc, CCRP

CONTACT

[email protected]

416-340-4800 ext. 4328

About this study

Cytomegalovirus (CMV) is the most common viral infection in transplant recipients and has major impacts on patient outcomes. It can cause fever, pneumonia, gastrointestinal disease, and lead to rejection of the kidney. To prevent this, transplant recipients receive prolonged antiviral drugs. This leads to significant drug toxicity and cost, and is often not successful. The risk of CMV is much higher if the donor organ carries latent CMV inside it (approximately 50-70% of donor organs). A much better and safer strategy would therefore be to try to eliminate the latent virus from the donor organ prior to transplantation. Ex Vivo Organ Perfusion (EVOP) is a common method of donor organ preservation and treatment which allows donor organs to be treated for several hours under close to physiological conditions.

The investigators propose a study in which kidneys will be treated prior to transplantation on the EVOP platform in order to decrease latent CMV. SYN002 is a novel compound that binds to cells that are latently infected with CMV and is internalized and kills those specific cells. This pilot study will involve 12 kidney transplant patients, who are receiving a kidney known to have latent CMV. The kidney will be treated with SYN002 on the EVOP system prior to transplantation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Recipient Inclusion Criteria:

  • Age ≥18 years
  • Listed for kidney transplantation
  • Either CMV seronegative or seropositive
  • Willing to provide written informed consent to take part in the trial
  • Willing and able to return for follow-up visits as scheduled in the protocol
  • Not participating in other interventional trials

Recipient Exclusion Criteria:

  • Listed for combined organ transplant (e.g. kidney-pancreas or kidney-liver)
  • Re-transplantation
  • HIV positive
  • Highly sensitized recipient with a PRA >=95
  • Planned use of belatacept or alemtuzumab immunosuppression (both non-approved drugs in Canada)
  • Unable or unwilling to comply with study procedures

Donor Inclusion Criteria:

  • Deceased donor
  • CMV seropositive (D+)
  • Donor kidney meets criteria for transplantation
  • Single renal artery (required anatomy to perform EVOP)

Donor Exclusion Criteria:

  • CMV seronegative
  • Donor kidney not suitable for transplantation

Treatment and study plan

SYN002

Drug

SYN002, a fusion protein targeting US28, a human cytomegalovirus (CMV) - specific virally encoded receptor expressed on both latent and lytic CMV-infected cells.

Primary outcomes

  1. Graft function

    Time frame: 4 weeks post-transplant

    Proportion of patients with a functioning graft at 4 weeks post-transplant defined as no longer needing dialysis at 4 weeks

Secondary outcomes

  1. Delayed graft function

    Time frame: 4 weeks post-transplant

    a. Proportion of patients with delayed graft function with requirement for dialysis post-transplant

  2. CMV DNAemia 3 months

    Time frame: 3 months post-transplant

    Proportion of patients that develop CMV DNAemia with plasma viral load > 1000 IU/ml at 3 months post-transplant

  3. Length of hospital stay

    Time frame: 6 months post-transplant

    Median days of hospital stay

  4. Graft survival 3 months

    Time frame: 3 months post-transplant

    Proportion of patients with a functioning graft

  5. Graft survival 6 months

    Time frame: 6 months

    Proportion of patients with a functioning graft

  6. CMV DNAemia 6 months

    Time frame: 6 months post-transplant

    Proportion of patients that develop CMV DNAemia with plasma viral load > 1000 IU/ml at 6 months post-transplant

  7. CMV disease

    Time frame: 6 months post-transplant

    Proportion of patients with CMV disease

Study contacts

Contact information is provided by the study sponsor or research team.

Atul Humar, MD, FRCP(C)

CONTACT

[email protected]

416-340-4241

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Registry information

Official study title

Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission: A Safety Trial in Kidney Transplant Recipients

Acronym: RESPECT-CMV

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 23, 2026
Registry last updated
Mar 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.